SCHEMBL3486168

SCHEMBL3486168

CCC(=O)CCCCC(N)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.55
NOS1 P29475 6/20 0.51
DDAH1 O94760 3/20 0.51
ARG2 P78540 4/20 0.50
ARG1 P05089 3/20 0.50
NOS2 P35228 5/20 0.49
NOS3 P29474 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
GRIK1 P39086 2/20 0.48
SLC1A2 P43004 2/20 0.48
SLC1A1 P43005 2/20 0.48
GRIK2 Q13002 2/20 0.48
GRM8 O00222 1/20 0.48
GRM6 O15303 1/20 0.48
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GRM5 P41594 1/20 0.48
GRIA1 P42261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7791775 0.98 GSR (0.53) GSRNOS1DDAH1ARG2ARG1
SCHEMBL7362969 0.98 GSR (0.53) GSRNOS1DDAH1ARG2ARG1
SCHEMBL15342759 0.85 GRIK1 (0.60) GSRNOS1DDAH1CYP1A2GRIK1
SCHEMBL10076866 0.85 GRIK1 (0.60) GSRNOS1DDAH1CYP1A2GRIK1
SCHEMBL28818201 0.85 GRIK1 (0.59) GSRNOS1DDAH1NOS2GRIK1
SCHEMBL28007614 0.85 GRIK1 (0.59) GSRNOS1DDAH1NOS2GRIK1
SCHEMBL28007603 0.85 GRIK1 (0.59) GSRNOS1DDAH1NOS2GRIK1
SCHEMBL28921485 0.85 GRIK1 (0.59) GSRNOS1DDAH1NOS2GRIK1
SCHEMBL27363028 0.85 GRIK1 (0.59) GSRNOS1DDAH1NOS2GRIK1
SCHEMBL28007955 0.85 GRIK1 (0.59) GSRNOS1DDAH1NOS2GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4673157-A2 COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME Persephone Biosciences, Inc. (US) 2026-01-07 EP disclosed
WO-2024182434-A2 COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME PERSEPHONE BIOSCIENCES, INC. (US) 2024-09-06 WO disclosed
US-10920283-B2 Methods to establish and restore normal gut microbiota function of subject in need thereof WASHINGTON UNIVERSITY 2021-02-16 US disclosed
US-20170281740-A1 SERODIAGNOSIS OF SALMON POISONING DISEASE OHIO STATE INNOVATION FOUNDATION 2017-10-05 US disclosed
EP-3132021-A2 AMMONIA-OXIDIZING NITROSOMONAS EUTROPHA STRAIN D23 Aobiome LLC (US) 2017-02-22 EP disclosed
US-20170037363-A1 AMMONIA-OXIDIZING NITROSOMONAS EUTROPHA STRAIN D23 AOBIOME LLC (US) 2017-02-09 US disclosed
US-20160326574-A1 METHODS TO ESTABLISH AND RESTORE NORMAL GUT MICROBIOTA FUNCTION OF SUBJECT IN NEED THEREOF WASHINGTON UNIVERSITY 2016-11-10 US disclosed
WO-2015160911-A2 AMMONIA-OXIDIZING NITROSOMONAS EUTROPHA STRAIN D23 AOBIOME LLC (US) 2015-10-22 WO disclosed
WO-2015066625-A1 METHODS TO ESTABLISH AND RESTORE NORMAL GUT MICROBIOTA FUNCTION OF SUBJECT IN NEED THEREOF WASHINGTON UNIVERSITY (US) 2015-05-07 WO disclosed
US-20100028952-A1 FERMENTATION AND PURIFICATION OF ACTINOMADURA CHROMOPROTEIN AND RELATED SPECIES WYETH (US) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028952-A1 FERMENTATION AND PURIFICATION OF ACTINOMADURA CHROMOPROTEIN AND RELATED SPECIES DCXR, ACTR2, AMY2A GSR 2502/4885NOS1 3065/4885DDAH1 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.